M.D., MPH, FACP, FAAHPM, FASCO, Medical Director, Medical Oncology Programs and Genetics, AIM Specialty Health
Dr. Fisch is the Medical Director of Medical Oncology Programs and Genetics for AIM. He works closely with the executive leadership team to provide clinical expertise for the expansion of the AIM Medical Oncology Solution and for the AIM Genetic Testing Solution. Prior to AIM, Dr. Fisch was a faculty member at MD Anderson Cancer Center in Houston, initially in the Department of Palliative Care and Rehabilitation. He then led the MD Anderson Community Clinical Oncology Program (CCOP) Research Base. He subsequently served as the founding chair of the Department of General Oncology. In this role, Dr. Fisch led a group of clinical faculty involved in clinical and basic research, and the management of patients in community and academic settings. In addition, Dr. Fisch was co-chair of the NCI Symptom Management and Quality of Life Committee from 2007 to 2014. Other national service roles include chairing the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Symptom Science and Treatment Toxicity Committee, the SWOG Social Media Working Group, and the first American Society of Clinical Oncology (ASCO) Palliative Care in Oncology Symposium.Currently Dr. Fisch is co-chair of the SWOG Symptom Control and Quality of Life Committee and a member of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC). Dr. Fisch completed his undergraduate, medical school, and internal medicine training at the University of Virginia, and his hematology/oncology fellowship training at Indiana University. He also received his Master’s in Public Health at Indiana University. He is board-certified in medical oncology, internal medicine, and hospice and palliative medicine, and has been honored by election to fellowship by the professional societies in each of these disciplines.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: As of today, there is a definite lack of concrete and consistent reimbursement methodologies in support of precision medicine, especially when it comes to genetic testing. It is time to start formulating plans and proposals, and to put a framework or guidelines in place to arrive at a common ground. This panel, with various representatives from across health care includes health care providers, health care system operators, payors, and testing services providers, will kick-start this much needed conversation.